Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment

  • Veru Inc VERU has submitted an emergency use authorization (EUA) for sabizabulin application to FDA for COVID-19 treatment.
  • The application covers moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS).
  • The EUA submission is based on the positive results from the Phase 3 COVID-19 clinical trial evaluating the efficacy and safety of sabizabulin in approximately 204 hospitalized COVID-19 patients at high risk for ARDS and death. 
  • Related: Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients.
  • "COVID-19 new cases and hospitalizations are on the rise again with a summer and fall-winter peaks expected," said Mitchell Steiner, Chairman, President, & CEO.
  • Veru is in Discussions with other regulatory agencies globally regarding emergency use authorization for sabizabulin, including the European Medicines Agency.
  • The company prepares for the U.S. Commercial Launch if EUA is granted.
  • Price Action: VERU shares are up 14.70% at $15.57 during the market session on the last check Tuesday.

Posted In: BriefsCOVID-19 Coronaviruswhy it's movingBiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.